Research programme: CNS biotherapeutics - Axial Biotherapeutics/California Institute of Technology
Latest Information Update: 21 Dec 2016
At a glance
- Originator California Institute of Technology/CalTech
- Developer Axial Biotherapeutics; California Institute of Technology/CalTech
- Class Bacteria
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurological disorders